Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Poerzgen

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|June 20, 2018
Botanicals and HepatotoxicityMarina M Roytman, Peter Poerzgen, Victor Navarro
Hepatology International|March 31, 2016
Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestryMarina Roytman, Resham Ramkissoon, Christina Wu, et al.
Hawai'I Journal of Medicine & Public Health : a Journal of Asia Pacific Medicine & Public Health|January 22, 2016
Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment ResponseChristina J Wu, Marina M Roytman, Leena K Hong, et al.
Journal of Natural Products|October 12, 2017
Scalaradial Is a Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion ChannelsJohn G Starkus, Peter Poerzgen, Kristine Layugan, et al.
ALTEX|October 9, 2008
The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapyMarcel Leist, Susanne Bremer, Patrik Brundin, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|June 20, 2018
Botanicals and HepatotoxicityMarina M Roytman, Peter Poerzgen, Victor Navarro
Hepatology International|March 31, 2016
Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestryMarina Roytman, Resham Ramkissoon, Christina Wu, et al.
Hawai'I Journal of Medicine & Public Health : a Journal of Asia Pacific Medicine & Public Health|January 22, 2016
Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment ResponseChristina J Wu, Marina M Roytman, Leena K Hong, et al.
Journal of Natural Products|October 12, 2017
Scalaradial Is a Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion ChannelsJohn G Starkus, Peter Poerzgen, Kristine Layugan, et al.
ALTEX|October 9, 2008
The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapyMarcel Leist, Susanne Bremer, Patrik Brundin, et al.
Pageof 1